ERBB2 and breast cancer: Additionally, HER2 overexpression has been exploited as a potential therapeutic target for the clinical management of HER2 + BC patients, as in the case of monoclonal antibodies (trastuzumab, TZ, and more recent derivatives) directed against HER2 [8].